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Introduction
Protein N-glycosylation affects glycoprotein structure and func-
tion during protein folding, trafficking and clearance, cell–cell 
interactions, and signal transduction (Dennis et al., 2009; Varki 
and Lowe, 2009). N-glycans are synthesized by a series of 
glycosyltransferases and glycosidases along the secretory path-
way (Stanley et al., 2009). Golgi resident glycosyltransferases are 
typically type II transmembrane proteins with a short, N-terminal 
cytoplasmic tail, a transmembrane domain, and a large, C-terminal 
catalytic domain (Cantarel et al., 2009). Some glycosyltransfer-
ases, including protein O-mannosyltransferases 1 and 2 (Akasaka-
Manya et al., 2006) and T-synthase (Ju et al., 2008; Aryal et al., 
2010), are regulated by a protein chaperone or complex required 
for transferase activity. Here we identify a novel inhibitor of a 
glycosyltransferase activity that is expressed primarily in testic-
ular germ cells.
Glycosyltransferases with similar sequences may catalyze 
related enzyme reactions, use the same nucleotide-sugar, or 
have the same substrate specificity. About 90 glycosyltransfer-
ase families have been classified in the carbohydrate-active   
enzymes database (CAZy; Cantarel et al., 2009). However, new 
glycosyltransferase activities cannot be predicted merely by   
sequence or homology comparisons. For example, the T-synthase   
chaperone Cosmc is highly homologous to a 1,3-galactosyl-
transferase  but  has  no  known  transferase  activity  (Ju  and   
Cummings, 2002; Kudo et al., 2002). In addition, glycosyltrans-
ferase genes give rise to numerous splice forms that may pro-
duce enzymes of different activity or specificity (Thierry-Mieg 
and Thierry-Mieg, 2006). For example, 4GalT-I has two tran-
scripts with different transcription initiation sites, producing a 
long form with an extra 13 amino acids at its N terminus that is 
localized to the cell surface, and a short form localized to the 
trans-Golgi (Shur et al., 1998; Rodeheffer and Shur, 2002).
To characterize new “orphan” glycosyltransferases, can-
didates may be expressed in wild-type CHO cells or CHO mu-
tants with altered glycosylation that have a well-characterized 
glycan complement (Patnaik and Stanley, 2006; North et al., 
2010). CHO glycosylation mutants express changes in cell sur-
face glycans that are recognized by cytotoxic plant lectins. Lectin- 
resistant phenotypes reflect mutations in glycosylation genes,   
such as glycosyltransferase, glycosidase, or nucleotide-sugar 
transporter genes (Patnaik and Stanley, 2006; North et al., 2010). 
D
atabase analyses identified 4933434I20Rik as a 
glycosyltransferase-like gene expressed mainly in 
testicular germ cells and regulated during sper-
matogenesis. Expression of a membrane-bound form   
of the protein resulted in a marked and specific reduction   
in N-acetylglucosaminyltransferase I (GlcNAcT-I) activity 
and complex and hybrid N-glycan synthesis. Thus, the 
novel  activity  was  termed  GlcNAcT-I  inhibitory  protein 
(GnT1IP). Membrane-bound GnT1IP localizes to the ER, 
the ER-Golgi intermediate compartment (ERGIC), and the 
cis-Golgi. Coexpression of membrane-anchored GnT1IP 
with GlcNAcT-I causes association of the two proteins,   
inactivation of GlcNAcT-I, and mislocalization of GlcNAcT-I 
from the medial-Golgi to earlier compartments. Therefore, 
GnT1IP is a regulator of GlcNAcT-I and complex and 
hybrid N-glycan production. Importantly, the formation 
of high mannose N-glycans resulting from inhibition of 
GlcNAcT-I by GnT1IP markedly increases the adhesion of 
CHO cells to TM4 Sertoli cells. Testicular germ cells might 
use GnT1IP to induce the expression of high mannose   
N-glycans on glycoproteins, thereby facilitating Sertoli–germ 
cell attachment at a particular stage of spermatogenesis.
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sorted for high GFP expression were uniformly highly resistant 
to L-PHA (Fig. 1 A, line 5). Similar results were found for Myc-
BAB30173.1 (not depicted). Both proteins contain 
253EDD
255,   
a motif that might mediate nucleotide-sugar and metal ion 
binding in a glycosyltransferase reaction (Breton and Imberty, 
1999). However, mutation to either E253A (ADD) or D255A 
(EDA) did not diminish the L-PHA resistance induced by Myc-
NP_080509.2 (not depicted). In addition, when mouse GlcNAcT-I 
was  transiently  expressed  in  Lec1/Myc-NP_080509.2  stable 
transfectants,  it  was  also  inhibited  because  the  introduced 
GlcNAcT-I failed to reverse the Con A hypersensitivity of Lec1 
(not depicted).
In vitro GlcNAcT-I activity was also inhibited in lysates 
from GFP-sorted CHO/Myc-NP_080509.2 transfectants, but 
4GalT activity was not affected (Fig. 1 B). Similarly, when 
mouse GlcNAcT-I was coexpressed with Myc-NP_080509.2 in 
Lec1 mutant cells, GlcNAcT-I activity was inhibited, but 4GalT 
activity was not (Fig. 1 C). However, no inhibition of GlcNAcT-I 
was observed when lysates from Lec1 cells expressing only 
GlcNAcT-I or only Myc-NP_080509.2 were mixed (not depicted), 
indicating that the proteins had to be coexpressed for GlcNAcT-I 
activity to be inactivated. Thus, the introduction of NP_080509.2 
into wild-type CHO cells inhibited GlcNAcT-I but not 4GalT 
activity, and induced a lectin resistance phenotype characteris-
tic of Lec1 cells that lack GlcNAcT-I. We therefore termed the 
novel activity GlcNAcT-I inhibitory protein (GnT1IP).
Two GnT1IP transcripts are expressed in 
mouse testicular germ cells
Previous reports showed that mouse 4933434I20Rik is up- 
regulated at the transcriptional and translational levels in spermato-
cytes during spermatogenesis (Iguchi et al., 2006; Chalmel   
et al., 2007). Northern blot analysis of total RNA from mouse 
tissues detected GnT1IP transcripts of 1.2 kb and 2.2 kb   
(5 probe), and 1.8 kb and 2.2 kb (3 UTR probe) only in 
testis (unpublished data), as also observed for a 3 UTR probe 
in the SymAtlas microarray database (Su et al., 2004). The human 
homologue of GnT1IP (UniProtKB A6NG13) was also detected 
only in testis by Northern blot analysis (Hodgson et al., 2006). 
Rapid amplification of cDNA ends (RACE) from testis RNA 
revealed that transcription may stop at either of two poly(A
+) 
signals in the 3 UTR, and that two ATGs might serve as trans-
lational start sites for cDNAs NM_026233.2 and U009551-3 
(NIA Mouse Gene Index; Fig. 1 D). RT-PCR of total testis RNA 
using primers from genomic DNA sequence upstream of the 
NM_026233.2 cDNA detected a 5 ATG occurring after a 
CCACG Kozak-like sequence (Fig. 1 D). This transcript, encoding 
a protein with 44 additional N-terminal amino acids, was termed 
GnT1IP-L and given the Genbank/EMBL/DDBJ accession no. 
HM067443 (Fig. S1). GnT1IP encoded by the NM_026233.2 
cDNA was termed GnT1IP-S. GnT1IP transcripts were detected 
in cDNAs generated from adult mouse testis total and poly(A
+) 
RNA (Fig. 1 D). GnT1IP-S homologues exist in rat and human, 
but GnT1IP-L has been found only in mouse to date. GnT1IP 
appears to occur only in mammals and aa sequences are well 
conserved between mammalian species, with mouse and human 
being 63% identical and 78% similar.
For instance, LEC10 CHO mutants have a gain-of-function   
mutation that induces expression of the Mgat3 gene and Mgat3 
(GlcNAcT-III) catalyzes the transfer of the bisecting GlcNAc to 
complex N-glycans (Campbell and Stanley, 1984; Stanley et al., 
2005). The addition of this single residue to N-glycans causes 
cells to become highly resistant to ricin and hypersensitive to 
the  erythroagglutinin  E-PHA  (Campbell  and  Stanley,  1984). 
Lec1  CHO  glycosylation  mutants  have  a  loss-of-function   
mutation in the Mgat1 gene and lack Mgat1 (GlcNAcT-I) ac-
tivity (Chen and Stanley, 2003). GlcNAcT-I is the medial-Golgi 
glycosyltransferase that transfers GlcNAc to Man5GlcNAc2 to   
initiate hybrid and complex N-glycan synthesis (Stanley et al., 
2009). Lec1 mutants lack hybrid and complex N-glycans and 
are consequently resistant to many plant lectins that bind to ter-
minal sugars of N-glycans (Stanley, 1983). By contrast, Lec1 
cells are hypersensitive to lectins like Con A that bind high 
mannose N-glycans. Expression of an orphan glycosyltransfer-
ase that alters the lectin resistance phenotype of wild-type CHO 
cells or of CHO glycosylation mutants allows identification of 
the new activity.
Using this strategy we characterized a putative mouse   
glycosyltransferase encoded by the gene 4933434I20Rik with 
37% identity to mouse GlcNAcT-IVa and 46% identity to mouse 
GlcNAcT-IVb (CAZy GT54). Here we show that CHO trans-
fectants expressing membrane-bound forms of this protein have 
a Lec1 lectin resistance phenotype due to the specific inhibition 
of GlcNAcT-I activity. The novel activity, termed GlcNAcT-I 
inhibitory protein (GnT1IP), is expressed mainly in spermato-
cytes and spermatids of mammalian testis, its transcription and 
translation are tightly regulated during mouse spermatogenesis, 
and the changes in glycan complement it induces cause cells to 
adhere strongly to TM4 Sertoli cells.
Results
A novel inhibitor of complex and hybrid  
N-glycan synthesis
Database searches identified mouse gene 4933434I20Rik and 
cDNA NM_026233.2 as encoding sequences similar to the 
GlcNAcT-IV glycosyltransferase family in CAZy family GT54 
(Cantarel et al., 2009). Deduced protein NP_080509.2 is 37% 
identical to mouse Mgat4A (GlcNAcT-IVa) and 46% identical 
to mouse Mgat4B (GlcNAcT-IVb) and has an identical se-
quence  to  BAB30173.1  except  for Asp  instead  of Asn  in   
NP_080509.2 at the fifth aa. The TMpred program (Hofmann 
and Stoffel, 1993) predicted that NP_080509.2 contains a 
transmembrane domain from aa 5–25, whereas SignalP 3.0 
(Emanuelsson et al., 2007) predicted a signal peptide from aa 1–26, 
and a GlcNAcT-IV–like domain from aa 79–373. N-terminal 
Myc-tagged BAB30173.1 was previously shown to localize to 
the ER when transiently expressed in HeLa cells (Fink et al., 
2006; Sprenger et al., 2008).
The bicistronic vector pIRES2-EGFP was used to stably 
express  N-terminal  Myc-tagged  NP_080509.2  in  wild-type 
CHO cells. A mixed transfectant population (Fig. 1 A, line 4) 
contained cells highly resistant to the leukoagglutinin L-PHA, 
similar to Lec1 mutant cells (Fig. 1 A, line 2). Stable transfectants 895 A novel inhibitor of GlcNAcT-I • Huang and Stanley
of GnT1IP-S-HA (Fig. 2 A, GnT1IP-S-Tag) in cell lysate was 
modified with both complex and high mannose N-glycans   
(Fig. S2 A), but internally tagged SP-HA-GnT1IP-S (Fig. 2 A, 
SP-iTag2-GnT1IP-S) in cell lysate had only Endo H–sensitive 
high mannose N-glycans (Fig. S2 B). By contrast, N-terminally 
tagged FL-HA-GnT1IP-S (Fig. 2 A, Tag-GnT1IP-S) was not 
secreted (not depicted). Thus, N-terminal membrane-anchored 
forms of GnT1IP carry N-glycans reflecting confinement to the 
ER, cis- and early medial-Golgi compartments.
The C-terminal sequence of GnT1IP is KDNYY, which 
could be an ER membrane retention signal (Teasdale and Jackson, 
1996). To investigate, a Myc tag was inserted before KDNYY 
(Fig. 2 A, GnT1IP-L-iTag1). GnT1IP-L-Myc-KDNYY was 
detected primarily in the Golgi in HeLa cells permeabilized   
using Triton X-100, but was not detected in cells treated with   
a low concentration of digitonin to permeabilize the plasma 
membrane  and  expose  cytoplasmic  protein  domains  (Fig.  2,   
C and D). Antibodies to the C-terminally tagged lumenal do-
main of CHO GlcNAcT-I-HA in the medial-Golgi and to the   
lumenal domain of trans-Golgi endogenous 4GalT-I behaved 
GnT1IP-L is a type II transmembrane 
protein and GnT1IP-S may be secreted
Constructs of GnT1IP-L and -S with various tags were gener-
ated to investigate their intracellular localization (Fig. 2 A).   
To determine if GnT1IP-L or -S traverses the medial-Golgi,   
lysates from CHO transfectants were digested with enzymes that 
remove N-glycans. N-terminally tagged HA-GnT1IP-L (Fig. 2 A,   
Tag-GnT1IP-L) was sensitive to digestion with both endoglycosi-
dase H (Endo H) and peptide-N-glycosidase F (PNGase F; 
Fig. 2 B), showing that HA-GnT1IP-L was modified with high 
mannose or hybrid N-glycans found on glycoproteins localized 
to the ER and cis- to early medial-Golgi. N-terminally tagged 
FL-HA-GnT1IP-S (Fig. 2 A, Tag-GnT1IP-S) also carried only 
high mannose or hybrid N-glycans (Fig. 2 B), supporting a 
previous finding that Myc-GnT1IP-S localized to the ER and 
cis- to medial-Golgi in HeLa cells (Fink et al., 2006; Sprenger 
et al., 2008). However, when GnT1IP-S had a C-terminal tag 
(Fig. 2 A, GnT1IP-S-Tag) or an internal tag (Fig. 2 A, SP-iTag2-
GnT1IP-S), it was partially secreted with complex N-glycans 
resistant to digestion with Endo H (Fig. S2, A and B). A proportion 
Figure 1.  Expression of NP_080509.2 in CHO cells inhibits GlcNAcT-I. (A) L-PHA resistance of CHO, Lec1 cells, or CHO cells stably expressing GFP or 
Myc-NP_080509.2 or Myc-NP_080509.2
GFP sorted for GFP. Cells were stained with Methylene Blue when control wells with no L-PHA became confluent. 
The highest L-PHA concentration was 70 µg/ml. (B) GlcNAcT-I and 4GalT activities in lysates from CHO cells stably expressing Myc-NP_080509.2
GFP. 
Error bars = SD; n = 3. (C) GlcNAcT-I and 4GalT activities in lysates of Lec1 cells transiently expressing GFP, GFP and GlcNAcT-I, or Myc-NP_080509.2 
and GlcNAcT-I. Myc-NP_080509.2 (2x) received 2x cDNA. Bars represent range (n = 2). (D) Diagram of mouse cDNAs NM_026233.2, AK017057.1, 
and U009551-3, and the predicted products of RT-PCR. Primer pairs 1, 4, 6 detect only GnT1IP-L; pairs 2, 3, 5, 7 detect both GnT1IP-L and -S. Left panel, 
RT-PCR of adult testis total RNA with primer pairs 1–5. Right panel, RT-PCR of testis poly(A
+) RNA with primer pairs 6 and 7.JCB • VOLUME 190 • NUMBER 5 • 2010   896
membrane-bound Myc- or FL-HA-GnT1IP-S (Fig. 1 A; Table I), 
unanchored versions of GnT1IP-S did not induce the Lec1 lectin 
resistance phenotype in wild-type CHO cells (Table I). In addi-
tion, wild-type CHO cells stably expressing GnT1IP-S with a 
C-terminal KDEL ER retrieval sequence did not become L-PHA 
resistant (Table I).
GnT1IP-L differs from GnT1IP-S by 44 N-terminal amino 
acids, which apparently convert the signal peptide of GnT1IP-S 
into a type II transmembrane domain in GnT1IP-L. Consistent 
with this, wild-type CHO cells stably expressing untagged   
GnT1IP-L or GnT1IP-L-Myc-KDNYY had markedly increased 
L-PHA resistance, indicating inhibition of GlcNAcT-I (Fig. 3 A).   
When  hygromycin-resistant  transfectants  expressing  Myc- 
GnT1IP-L were enriched by FACS sorting using the agglutinin 
Galanthus nivalus (GNA), a plant lectin that binds high mannose 
N-glycans, the GNA-positive population contained markedly more 
Myc-GnT1IP-L (Fig. 3 B), and was more resistant to L-PHA   
(not depicted), similar to cells expressing untagged GnT1IP-L.
similarly (not depicted). By contrast, and as expected for type II 
transmembrane glycosyltransferases, N-terminally tagged Myc-
GnT1IP-L was detected after treatment with either a low concen-
tration of digitonin or Triton X-100, showing it was accessible 
to Ab in the cytoplasm (Fig. 2, C and D). Therefore, GnT1IP-L, 
like  GlcNAcT-I  and  4GalT-I,  is  a  type  II  transmembrane   
protein with an N-terminal cytoplasmic tail. However, neither 
N- nor C-terminally tagged GnT1IP-L exhibited tight Golgi 
localization like GlcNAcT-I-HA, and partially colocalized with 
4GalT-I (Fig. S2 D).
Only GnT1IP-L and membrane-anchored 
GnT1IP-S inhibit GlcNAcT-I
The N- and C-terminally tagged forms of GnT1IP-S exhibited 
different trafficking properties and may therefore have different 
abilities to inhibit GlcNAcT-I. To investigate, wild-type CHO 
cells stably expressing different GnT1IP-S constructs were ex-
amined for their ability to induce lectin resistance. In contrast to 
Figure 2.  GnT1IP-L is a type II transmembrane glycoprotein with high mannose N-glycans. (A) GnT1IP constructs showing the N-terminal cytosolic domain 
of GnT1IP-L (aa 1–48; black box); the predicted transmembrane domain of GnT1IP-L (aa 49–69; white box) or signal peptide (SP) of GnT1IP-S (aa 1–26);   
the Golgi lumenal domain (aa 70–417 for GnT1IP-L and aa 27–373 for GnT1IP-S; gray box), and the C-terminal deletion mutants Tag-GnT1IP-S-CD1 (39 aa 
deletion) and -CD2 (122 aa deletion); Tag represents FLAG-HA (FL-HA), HA, or Myc; internal tags were inserted after aa 412 of GnT1IP-L (iTag1) and 
after aa 26 of GnT1IP-S (iTag2); the 48 aa stem-region deletion ( stem) from aa 71–118 in GnT1IP-L and aa 27–74 in GnT1IP-S is shown by a hat. The 
KDEL sequence was inserted after aa 373 of GnT1IP-S. (B) Lysates from CHO cells expressing HA-GnT1IP-L or FL-HA-GnT1IP-S digested with PNGase F or 
Endo H (+) or incubated without enzyme () and subjected to immunoblotting using anti-HA mAb (IB HA). (C) HeLa cells transiently expressing Myc-GnT1IP-L 
or GnT1IP-L-Myc-KDNYY were fixed, treated with 5 µg/ml digitonin or (D) 0.2% Triton X-100, immunolabeled for Myc-tagged GnT1IP-L (green) and actin 
(phalloidin; red), and observed by fluorescence microscopy. Bars, 20 µm.897 A novel inhibitor of GlcNAcT-I • Huang and Stanley
activity,  but  GlcNAcT-III  and  4GalT  activities  were  not   
affected (Fig. 3 E). The deletion mutant Myc-GnT1IP-S-CD1 
had no effect on GlcNAcT-I, GlcNAcT-III, or 4GalT activity 
(Fig. 3 E). This result was confirmed in wild-type CHO cells 
stably expressing a mouse cDNA encoding GlcNAcT-III-HA 
and transiently expressing the different GnT1IP constructs (not 
depicted). Finally, it was shown that GnT1IP-L and membrane-
bound GnT1IP-S induced the same changes in N-glycan com-
plement using MALDI-TOF mass spectrometry of the N-glycans 
released from glycoproteins of stable CHO cell transfectants 
(Fig. S3). Cells expressing either GnT1IP-L or Myc-GnT1IP-S 
produced  markedly  more  of  the  Man5GlcNAc2  substrate  of 
GlcNAcT-I than wild-type CHO cells, and synthesized very few 
complex N-glycans, consistent with a similar degree of inhibi-
tion of GlcNAcT-I activity.
GnT1IP-L is localized to the ER, ERGIC, 
and cis-Golgi compartments
When N- or C-terminally tagged GnT1IP-L was transiently ex-
pressed  in  HeLa  cells,  each  colocalized  with  GM130,  a  cis- 
Golgi marker (Fig. 4 A; and not depicted). GnT1IP-L also   
partially colocalized with ERGIC-53 and an ER marker, protein 
disulfide isomerase (PDI; Fig. 4 A; and not depicted). Membrane-
anchored Tag-GnT1IP-S was also primarily localized in the   
Golgi and ERGIC and partially in the ER, similar to GnT1IP-L 
(Fig. S4 A). The stem-region deletion mutants of N-terminally 
tagged GnT1IP-L and -S were also localized to the ER, cis-Golgi, 
and probably the ERGIC compartment (Fig. 4 B; Fig. S4 B). By 
contrast, the C-terminal deletion mutants of membrane-bound 
To determine which region(s) of GnT1IP are important 
for inducing L-PHA resistance, deletion mutants of GnT1IP-S 
lacking 39 aa (Fig. 2 A, Tag-GnT1IP-S-CD1) or 121 aa (Fig. 2 A, 
Tag-GnT1IP-S-CD2) from the C terminus, or a stem region   
deletion of 48 aa (Fig. 2 A, Tag-stem-GnT1IP-S or -L), were 
constructed. None of the deletion mutants induced L-PHA   
resistance in CHO transfectants (Fig. 3 A; Table I), although   
all constructs were expressed at similar levels based on immuno-
blotting, and GnT1IP transcript levels (not depicted). All mem-
brane-bound GnT1IP-L and GnT1IP-S deletion mutants were 
sensitive to Endo H digestion (not depicted), and thus were 
localized to the ER and early Golgi compartments.
Consistent with their ability to induce L-PHA resistance, 
GnT1IP-L  and  Tag-GnT1IP-L  reduced  GlcNAcT-I  but  not 
4GalT activity in CHO stable transfectants (Fig. 3 C). When 
Myc-GnT1IP-S was transiently expressed in Lec1 cells that had 
been  rescued  by  GlcNAcT-I-HA,  GlcNAcT-I  activity  was  re-
duced but GlcNAcT-I protein levels were not affected (Fig. 3 D). 
The  two  GlcNAcT-I-HA  forms  observed  probably  reflect   
O-glycosylation as shown for human GlcNAcT-I (Opat et al., 
2000) and as predicted by NetOGlyc 3.1 (Julenius et al., 2005).
To determine if GnT1IP inhibits an unrelated medial-
Golgi enzyme, GlcNAcT-III that is endogenously expressed   
in LEC10 CHO glycosylation mutant cells was examined.   
Myc-GnT1IP-L and -S induced L-PHA resistance in LEC10 
cells and the deletion mutant Myc-GnT1IP-S-CD1 did not (un-
published data), similar to their effects on wild-type CHO cells. 
LEC10 CHO stable transfectants expressing Myc-GnT1IP-L or -S 
and sorted for GNA binding had markedly reduced GlcNAcT-I 
Table I. Lectin resistance of CHO cells stably expressing GnT1IP-L or -S
Construct transfected Selection method
a L-PHA WGA
GnT1IP-L Hygro >10R
b nd
c
GnT1IP-L GNA-sorted >10R nd
Tag-GnT1IP-L Hygro >10R 7R
Tag-GnT1IP-L GNA-sorted >10R nd
GnT1IP-L-Tag Hygro >10R nd
GnT1IP-L-iTag1-KDNYY Hygro >10R nd
Tag-stem-GnT1IP-L Hygro –
d nd
GnT1IP-S G418 – –
GnT1IP-S-KDEL Hygro – –
Tag-GnT1IP-S G418 or Hygro >10R 3R
Tag-GnT1IP-S GFP-sorted >10R >8R
Tag-GnT1IP-S (E263A or D265A) G418 >10R 3R
GnT1IP-S-Tag Hygro – –
SP-iTag2-GnT1IP-S G418 or Hygro – –
Tag-stem-GnT1IP-S Hygro – –
Tag-GnT1IP-S-CD1 G418 or Hygro – –
Tag-GnT1IP-S-CD2 G418 or Hygro – –
CHO untransfected 5
e 2
e
CHO/vector or GFP G418 or Hygro – –
Lec1 untransfected >10R >8R
aTransfectants were selected for stable expression of constructs in hygromycin (Hygro) or G418 or sorted by flow cytometer for binding of GNA.
bNumber represents fold-change in lectin resistance from CHO; R, resistant.
cnd, not determined.
d–, no change in lectin resistance compared to CHO untransfected.
eConcentration of lectin in g/ml that kills 90% CHO cells.JCB • VOLUME 190 • NUMBER 5 • 2010   898
Figure 3.  GnTIP-L inhibition of GlcNAcT-I is specific and deletion mutants do not inhibit. (A) CHO cells stably expressing various GnT1IP-L constructs were 
tested for L-PHA resistance. Asterisk signifies that 50% cells survived at 70 µg/ml L-PHA. (B) CHO cells stably expressing Myc-GnT1IP-L after hygromycin 
selection (Myc-GnT1IP-L
Hyg) were sorted for GNA binding (Myc-GnT1IP-L
GNA) and analyzed by flow cytometry. Shaded profiles are autofluorescence.   
Lysates were analyzed by immunoblot (IB Myc), stripped and reprobed with anti-actin mAb. (C) GlcNAcT-I and 4GalT activities in lysates from CHO cells 
stably expressing vector or GNA-sorted GnT1IP-L
GNA or Myc-GnT1IP-L
GNA or HA-GnT1IP-L
GNA (GNA-sorted twice). Bars represent range (n = 2). (D) Lysates 
from Lec1 cells stably expressing GlcNAcT-I-HA and transiently expressing GFP or Myc-GnT1IP-S were assayed for GlcNAcT-I and 4GalT activities. Bars 
represent range of duplicates. Myc-GnT1IP-S and GlcNAcT-I-HA levels were determined by immunoblotting with actin as loading control. (E) GlcNAcT-I, 
GlcNAcT-III, and 4GalT specific activities (SA) in lysates from CHO and LEC10 cells stably expressing control vector or the GnT1IP construct shown. 
GnT1IP transfectants were GNA-sorted. Bars represent range (n = 2).899 A novel inhibitor of GlcNAcT-I • Huang and Stanley
exchange factor GBF1, and thereby causes retrograde transport 
of Golgi enzymes into the ER (Niu et al., 2005). HeLa cells tran-
siently expressing HA-GnT1IP-L were treated with cyclohexi-
mide (CHX) followed by BFA for 30 min after CHX removal. 
As expected, the medial-Golgi enzymes CHO GlcNAcT-I-HA 
(Fig. 4 D) and endogenous -mannosidase II (ManII, not depicted) 
were relocalized to the ER by BFA treatment. GnT1IP-L was 
also found in the ER and some GnT1IP-L was observed at ER 
exit sites, marked by ERGIC-53 (Fig. 4 D).
Myc-GnT1IP-S were primarily localized to the ER (Fig. 4 C; 
and not depicted).
To further investigate GnT1IP-L trafficking, the effects of 
brefeldin A (BFA) were examined under conditions in which 
matrix proteins such as GRASP65 and ERGIC-53, normally   
localized to the cis-Golgi and ERGIC, are redistributed to ER 
exit sites (Lippincott-Schwartz et al., 1989; Ward et al., 2001). BFA 
inhibits ADP-ribosylation factor 1 (Arf1) activation on the Golgi 
membrane by forming a complex with the guanine nucleotide   
Figure 4.  GnT1IP-L localizes to the ER, ERGIC, and Golgi. (A–C) HeLa cells transiently expressing different GnT1IP constructs were fixed, immunolabeled for 
Myc-tagged GnT1IP-L (red) and GM130 or PDI (green), or HA-tagged GnT1IP-L (green) and ERGIC-53 (red), followed by confocal microscopy (A and C) or   
fluorescence microscopy (B). (D) HeLa cells transiently expressing HA-GnT1IP-L or GlcNAcT-I-HA were treated with CHX for 45 min followed by BFA for   
30 min, fixed, immunolabeled for HA-GnT1IP-L or GlcNAcT-I-HA (green) and ERGIC-53 (red), and analyzed by fluorescence microscopy. Bars, 10 µm.JCB • VOLUME 190 • NUMBER 5 • 2010   900
Figure 5.  GnT1IP mislocalizes GlcNAcT-I-HA. (A) Myc-GnT1IP-L and -S were transiently coexpressed with GlcNAcT-I-HA in HeLa cells, fixed, immuno-
labeled for Myc (red) and for HA (green), and examined by confocal microscopy. Bars 10 µm. (B) Quantitation of effects of transiently expressed Myc-GnT1IP-L, 
Myc-GnT1Ip-S, or Myc-GnT1IP-S-CD1 on the localization of GlcNAcT-I-HA stably expressed in Lec1 cells. Localization in 300 cells per condition was 
classified into ER (E), more ER than Golgi (E/G), more Golgi than ER (G/E), or Golgi (G), and compared with Lec1 cells stably expressing GlcNAcT-I-HA 
alone. Error bars = SD; n = 3. (C) Deletion mutants of GnT1IP were coexpressed with GlcNAcT-I-HA in HeLa cells, fixed, immunolabeled for Myc (red) and 
for HA (green), and examined by immunofluoresence (top) or confocal microscopy (bottom). (D) Myc-GnT1IP-L was transiently expressed in HeLa cells, 
fixed, immunolabeled for Myc-GnT1IP-L (red) and endogenous ManII or 4GalT-I (green), and observed by fluorescence or confocal microscopy. (E) Myc-
GnT1IP-L was either transiently expressed alone or coexpressed with GlcNAcT-I-HA in HeLa cells overnight, CHX was added for 1 h, followed by CHX and 
BFA for 30 min, cells were fixed, immunolabeled for Myc-GnT1IP-L (red) and GlcNAcT-I-HA or endogenous ManII (green), and observed by fluorescence 
microscopy. White boxes in the middle panel are enlarged below. Bars, 10 µm.901 A novel inhibitor of GlcNAcT-I • Huang and Stanley
disrupted in the ER. Although endogenous ManII mislocalized 
to the ER with GlcNAcT-I-HA-KDEL in some cells (Fig. 6 D, 
top), in others its Golgi localization was unchanged (Fig. 6 D, 
middle).  Interestingly,  cells  in  which  GlcNAcT-I-HA-KDEL 
was highly expressed lost endogenous ManII completely, pre-
sumably due to ER degradation (Fig. 6 D, bottom).
GnT1IP interacts directly with GlcNAcT-I
Colocalization of GlcNAcT-I with GnT1IP-L in the ER indicated 
that GnT1IP-L might interact with GlcNAcT-I. To investigate, 
Myc-GnT1IP-L or -S or GlcNAcT1-Myc were cotransfected 
into CHO cells with various HA-tagged Golgi enzymes or a 
control HA-tagged protein, aa 321–600 of the p85 subunit of 
PI,3 kinase (HA-p85ni). Lysates were incubated with anti-Myc 
beads and bound proteins (IP Myc) were analyzed by immuno-
blotting (IB HA and IB Myc) as described in Materials and 
methods. Protein input blots showed that constructs were equiv-
alently expressed. IP Myc blots determined bound protein levels, 
as well as equivalence of anti-Myc beads based on the signal 
from immunoglobulin light chain.
Myc-GnT1IP-L on beads bound GlcNAcT-I-HA but did not 
bind the control HA-p85ni (Fig. 7 A, lane 1; blot IP Myc/IB HA). 
Coimmunoprecipitaiton  also  occurred  between  GlcNAcT- 
I-HA and Myc-GnT1IP-S (Fig. 7 B, lane 1). When the tags 
were reversed, HA-GnT1IP-L was pulled down by GlcNAcT-I-
Myc on beads (Fig. 7 C, lane 1). GlcNAcT-I-Myc also pulled 
down  the  medial-Golgi  resident  enzymes  GlcNAcT-III-HA   
and ManIIx-HA (Fig. 7 C, lanes 2 and 3), as anticipated based 
on previous evidence of kin recognition complexes between 
GlcNAcT-I and ManII. However, only a minor fraction of the 
short form of the trans-Golgi resident bovine 4GalT-I (SGT-
HA; Fig. 7 C, lane 4) was pulled down. Myc-GnT1IP-L and -S 
also  pulled  down  the  full-length  form  of  medial-Golgi 
GlcNAcT-III-HA (Fig. 7 A, lane 2; Fig. 7 B, lane 2) and   
ManIIx-HA was moderately coimmunoprecipitated by Myc-
  GnT1IP-L (Fig. 7 A, lane 3). However, trans-Golgi SGT-HA 
was not pulled down by either Myc-GnT1IP-L or -S (Fig. 7 A, 
lane 4; Fig. 7 B, lane 3). In summary, medial-Golgi enzymes 
GlcNAcT-I,  GlcNAcT-III,  and  ManIIx  coimmunoprecipi-
tated with membrane-bound GnT1IP-L and -S. However, only 
GlcNAcT-I enzyme activity was inhibited by membrane-bound 
GnT1IP-L and -S (Fig. 3 E).
Interestingly, secreted SP-HA-GnT1IP-S also interacted 
with GlcNAcT-I, the full-length GlcNAcT-III and ManIIx, but 
not the trans-Golgi sialyltransferase STX (Fig. S5 A). This is 
consistent with confocal microscopy results in which secreted 
SP-Myc-GnT1IP-S was partially colocalized with GlcNAcT-I-HA 
in the Golgi (Fig. S2 C). The C-terminal deletion mutant   
Myc-GnT1IP-S-CD2 pulled down GlcNAcT-I-HA, GlcNAcT-III- 
HA, and ManIIx-HA equivalently, but did not bind to SGT-HA 
(Fig. S5 B). Similarly, the stem-deletion mutant Myc-stem-
GnT1IP-L pulled down GlcNAcT-I-HA, full-length GlcNAcT-
III, and a minor fraction of SGT-HA (Fig. S5 C, lanes 2–4). 
However, the interaction between Myc-stem-GnT1IP-L and 
GlcNAcT-I-HA was somewhat weaker than between Myc- 
GnT1IP-L and GlcNAcT-I-HA (Fig. S5 C, lanes 1 and 2).   
All coimmunoprecipitations were specific because the N-terminal   
GnT1IP-L relocates GlcNAcT-I to the  
cis-Golgi, ERGIC, and ER
When N- or C-terminally tagged GnT1IP-L was transiently 
  coexpressed with GlcNAcT-I-HA in HeLa cells, a major pro-
portion of GlcNAcT-I was mislocalized to the ER (Fig. 5 A; 
and not depicted). A similar result was obtained when mem-
brane-bound Myc-GnT1IP-S was coexpressed with GlcNAcT-
I-HA in HeLa cells (Fig. 5 A). In Lec1 CHO cells, transient 
expression of GnT1IP-L or membrane-bound GnT1IP-S caused 
stably expressed GlcNAcT-I-HA to be mislocalized to the ER, 
and possibly the ERGIC and cis-Golgi compartments (Fig. 5 B). 
As expected, relocation by GnT1IP was specific for GlcNAcT-I 
and was not observed when GlcNAcT-I-HA was coexpressed 
with empty vector or the Golgi GDP-Fuc transporter Slc35c1, 
or the related multi-transmembrane Golgi protein Slc35c2 (not 
depicted). Most importantly, all deletion mutants of membrane-
bound GnT1IP failed to mislocalize GlcNAcT-I (Fig. 5 C; and 
not depicted). In GlcNAcT-I-HA–rescued Lec1 cells, Myc- 
GnT1IP-S-CD1 weakly affected GlcNAcT-I-HA Golgi localiza-
tion (Fig. 5 B). By contrast, overexpression of Myc-GnT1IP-L 
or -S did not result in ER localization for endogenous ManII or 
4GalT-I (Fig. 5 D; Fig. S4 B). Transient coexpression of either 
mouse GlcNAcT-III-HA or ManIIx-HA with cDNAs encoding 
various other proteins, or stable expression of GlcNAcT-III and 
ManIIx followed by transient expression of other proteins, all 
resulted in their mislocalization as well as affecting untrans-
fected cells, which prevented us from interpreting specific effects 
of GnT1IP on their intracellular localization.
Because GnT1IP-L caused GlcNAcT-I to go to the ER, BFA 
treatment was performed to determine if relocalized GlcNAcT-I 
was also in the cis-Golgi, ERGIC, and at ER exit sites. GlcNAcT-
I-HA  was  coexpressed  with  Myc-GnT1IP-L  in  HeLa  cells   
that were treated with BFA in the presence of CHX followed 
by immunofluorescence microscopy. Cells expressing both 
GlcNAcT-I-HA  and  Myc-GnT1IP-L  had  punctate  costaining 
around the nucleus, typical of ERGIC localization, in addition 
to reticular costaining of the ER, whereas endogenous ManII 
localized only to the ER in the presence of Myc-GnT1IP-L and 
did not colocalize with GnT1IP-L at punctate ER exit sites after 
BFA treatment (Fig. 5 E).
To determine if relocation of GlcNAcT-I to the ER might 
be sufficient to cause its inactivation, a CHO GlcNAcT-I- 
HA-KDEL construct was investigated. In Lec1 cells, GlcNAcT-I- 
HA-KDEL that colocalized in the ER with PDI (not depicted) 
partially rescued the Lec1 phenotype in a Con A resistance test 
(Fig. 6 A), and increased L-PHA binding (Fig. 6 B). Surprisingly, 
and despite its somewhat modest induction of lectin resistance, 
GlcNAcT-I-HA-KDEL  had  higher  GlcNAcT-I  activity  than 
GlcNAcT-I-HA in the in vitro GlcNAcT-I assay of cell lysate, 
though GlcNAcT-I-HA-KDEL was not more highly expressed 
than GlcNAcT-I-HA (Fig. 6 C). Transiently expressed GlcNAcT-
I-HA-KDEL also displayed higher activity than GlcNAcT-I-HA 
in  Lec1  cell  lysates  (not  depicted).  The  higher  activity  of 
GlcNAcT-I-HA-KDEL may reflect the environment of the ER 
versus the Golgi. In the Golgi GlcNAcT-I occurs in a kin recog-
nition  complex  with  ManII  and  GlcNAcT-II  (Nilsson  et  al., 
1994; Opat et al., 2000; Hassinen et al., 2010), which may be JCB • VOLUME 190 • NUMBER 5 • 2010   902
spermatogenesis at postnatal days 11, 17, and 22 and in post-
pubertal adult males at 13 wk. Transcription of GnT1IP-L and -S 
was up-regulated in 17-d mice and GnT1IP-S maintained a 
similar expression level from day 17 until the adult (Fig. 8 C). 
However, GnT1IP-L reached its highest expression level in 22-d 
testis, and was barely detected in the adult (Fig. 8 C). Primer 
pair 6, which detected only GnT1IP-L cDNA (Fig. 8 A), also 
showed that GnT1IP-L was reduced in expression after day 22 
(not depicted). In summary, GnT1IP-L and -S are expressed in 
mouse testicular germ cells, and GnT1IP-L expression is highly 
regulated during the first wave of spermatogenesis.
It was previously shown that truncated N-glycans occur-
ring in the ManIIx knockout mouse inhibit the binding of germ 
cells to Sertoli cells (Akama et al., 2002). To investigate whether 
high mannose N-glycans induced by the inhibition of GlcNAcT-I 
affect binding to Sertoli cells, CHO cells stably expressing   
HA-GnT1IP-L
GNA (GNA-sorted) or Myc-GnT1IP-S
GFP (GFP-
sorted) were tested for binding to mouse TM4 Sertoli cells 
deletion fragment of GlcNAcT-III-HA at 50 kD or control 
HA-p85ni were not pulled down by GlcNAcT-I, GnT1IP-L, or 
mutant constructs.
GnT1IP expression is highly regulated 
during mouse spermatogenesis
GnT1IP transcripts are present in testicular germ cells but not 
Sertoli cells (Chalmel et al., 2007). In mouse testis from post-
natal day 22 to the adult, GnT1IP transcripts are transported from 
ribonucleoprotein (RNP) particles that contain translationally 
inactive mRNA into translationally active polysomes (Iguchi   
et al., 2006). To investigate GnT1IP-L and -S in germ cells, total 
RNA  from  purified  mouse  spermatocytes  and  spermatids   
was subjected to RT-PCR with specific primer sets (Fig. 8 A).   
GnT1IP-L was expressed well in spermatocytes, but not in sper-
matids (Fig. 8 B). GnT1IP-S was expressed well in spermatids 
and probably in spermatocytes (Fig. 8 B). Transcriptional regu-
lation of GnT1IP was examined in testis during the first wave of 
Figure 6.  GlcNAcT-I-KDEL localized mainly in the ER is active. Lec1 cells stably expressing empty vector, GlcNAcT-I-HA-KDEL, or GlcNAcT-I-HA were ana-
lyzed for (A) Con A resistance and (B) L-PHA-FITC binding by flow cytometry. (C) GlcNAcT-I and 4GalT activities in transfectant lysates were determined. 
Bars represent range (n = 2). (D) HeLa cells transiently expressing GlcNAcT-I-HA-KDEL were fixed and immunofluorescently labeled for GlcNAcT-I-HA-KDEL 
(red) and endogenous ManII (green). Bars, 10 µm.903 A novel inhibitor of GlcNAcT-I • Huang and Stanley
Discussion
We describe here a novel mechanism of regulated inhibition   
of complex and hybrid N-glycan synthesis, by a newly identi-
fied activity termed GlcNAcT-I inhibitory protein, or GnT1IP. 
Membrane-bound forms of GnT1IP specifically inhibit GlcNAcT-I 
activity, leading to the termination of N-glycan synthesis in 
the medial-Golgi at the intermediate Man5GlcNAc2Asn. This 
causes cell surface glycoproteins to carry mainly high mannose 
N-glycans, thereby profoundly altering recognition of the cell 
by glycan-binding proteins such as galectins (Patnaik et al., 
2006). GnT1IP physically interacts with GlcNAcT-I and spe-
cifically inhibits GlcNAcT-I activity. Membrane-bound forms 
(Mather, 1980). Both transfectants bound much better to TM4 
Sertoli cells than control CHO cells expressing GFP alone (Fig. 8, 
D and E). Similar results were found for Myc-GnT1IP-S with 
fixed 15P-1 Sertoli cells (not depicted). Lec1 mutant CHO cells 
bound to Sertoli cells as well as the GnT1IP transfectants. Im-
portantly, Lec1 cells rescued with GlcNAcT-I-HA, which were 
sorted for L-PHA binding and the expression of complex   
N-glycans, lost their ability to adhere strongly to Sertoli cells 
(Fig. 8 F). Therefore, inhibition of GlcNAcT-I by GnT1IP dur-
ing spermatogenesis, leading to enhanced expression of high 
mannose N-glycans on germ cell glycoproteins, might be im-
portant for facilitating Sertoli–germ cell interactions during 
specific stages of spermatogenesis (Fig. 9).
Figure 7.  GnT1IP-L interacts with medial-Golgi but not trans-Golgi enzymes. (A) Myc-GnT1IP-L or (B) Myc-GnT1IP-S were coexpressed with GlcNAcT-I-HA, 
GlcNAcT-III-HA, ManIIx-HA, 4GalT-I lacking 13 N-terminal amino acids (SGT-HA), or aa 321–600 of the p85 subunit of PI3 kinase (HA-p85ni) in CHO 
cells. Lysates were immunoprecipitated with anti-Myc beads, and 40% of the beads were analyzed by immunoblotting on two blots (IP-Myc with IB-HA or 
IB-Myc). Input (1/40th lysate) was immunoblotted with IB-HA or IB-Myc. (C) GlcNAcT-I-Myc was coexpressed with HA-GnT1IP-L, GlcNAcT-III-HA, ManIIx-HA,   
or SGT-HA in CHO cells and lysates were treated as in A. , Fragment of GlcNAcT-III-HA not bound by GnT1IP; #, position or predicted position of   
HA-p85ni; *, immunoglobulin light chains from anti-Myc beads show equal concentration of beads.JCB • VOLUME 190 • NUMBER 5 • 2010   904
also  interacted  with  GlcNAcT-I,  consistent  with  immuno-
fluorescence microscopy showing GnT1IP-S colocalized in the 
Golgi with GlcNAcT-I. Soluble GlcNAcT-I also localizes to the 
Golgi in a complex with medial-Golgi enzymes before being 
secreted (Opat et al., 2000). We show here that GnT1IP-L asso-
ciates with the medial-Golgi enzymes ManIIx and GlcNAcT-
III, but does not inhibit the activity of GlcNAcT-III. GlcNAcT-I 
dynamically cycles between the ER and Golgi (Hoe et al., 1995; 
Opat et al., 2001), a cycle obviously interrupted by membrane-
bound GnT1IP. Perhaps membrane-bound GnT1IP disrupts the 
medial-Golgi complex that contains GlcNAcT-I by interacting 
with each component, prevents the GlcNAcT-I cycle, and spe-
cifically inhibits GlcNAcT-I activity. GnT1IP does not associate 
of GnT1IP cause GlcNAcT-I to become mislocalized to the cis-
Golgi, ERGIC, and ER. However, mislocalization by itself does 
not cause GlcNAcT-I to be inactivated because mislocalized 
GlcNAcT-I-KDEL is able to rescue the Lec1 CHO mutant to   
a good extent, and exhibits robust GlcNAcT-I activity in cell   
lysates. Cells highly expressing GlcNAcT-I-HA-KDEL in the 
ER either mislocalized endogenous ManII to the ER or led to   
its disappearance. Previous reports have shown that GlcNAcT-I 
occurs in a complex with ManII and GlcNAcT-II (Nilsson et al., 
1994, 1996; Opat et al., 2000; Hassinen et al., 2010).
GnT1IP deletion mutants did not inactivate or redirect 
GlcNAcT-I to the ER, but surprisingly did coprecipitate with 
GlcNAcT-I (Fig. S5). Secreted GnT1IP-S (SP-Myc-GnT1IP-S) 
Figure 8.  GnT1IP expression is regulated during spermatogenesis and enhances binding to Sertoli cells. (A) Diagram of GnT1IP cDNA and primer pairs 
for RT-PCR. (B and C) Total RNA from spermatocytes and spermatids partially purified from testes at postnatal day 11 (11 d) to 13 wk (13 w) was subjected 
to RT-PCR. Primer pair 6 detected only GnT1IP-L; pair 7 detected both GnT1IP-L and -S. Actin primers generated a 280-bp cDNA or 320-bp product from 
genomic DNA (*). Primer pairs 4 and 8 detected GnT1IP-L and -S coding regions. (D) Equal numbers of CHO cells stably expressing vector GFP, Myc-
GnT1IP-S, HA-GnT1IP-L, or Lec1 cells labeled with CFDA-SE were assayed for binding to TM4 Sertoli cells. Images of wells after washing were taken by 
fluorescence microscopy (FITC channel merged with phase contrast, 10x). Bars, 40 µm. (E) Three pictures taken from fields similar to those shown in D close 
to the center of each well were processed by NIH ImageJ software, green cells were counted, and triplicates averaged. Error bars = SD; n = 4 experiments. 
**, P < 0.01; *, P < 0.05 based on the two-tailed Student’s t test. (F) Lec1 cells expressing GlcNAcT-I-HA selected for hygromycin resistance or sorted for 
L-PHA binding (GlcNAcT-I-HA
L-PHA) were tested for binding to TM4 Sertoli cells as in D. Bars represent range (n = 2).905 A novel inhibitor of GlcNAcT-I • Huang and Stanley
GlcNAcT-I. GnT1IP-L expression is highly regulated during 
spermatogenesis (Fig. 8) and translation of GnT1IP transcripts 
is also strictly controlled (Iguchi et al., 2006). We have shown 
that  GnT1IP-induced  high  mannose  N-glycans  markedly  in-
crease cell adhesion to Sertoli cells (Fig. 8), indicating a poten-
tial role for the regulated expression of GnT1IP in the modulation 
of interactions between Sertoli and germ cells essential to sper-
matogenesis. Consistent with this, lectin studies suggest com-
plementary expression of high mannose and complex N-glycans 
in rat testes (Jones et al., 1992). Thus, L-PHA binding to com-
plex N-glycans is decreased during the transition from sper-
matogonia to spermatocytes, whereas Con A binding to high 
mannose N-glycans increases. Later in spermatogenesis, com-
plex N-glycans replace high mannose N-glycans to become the 
major N-glycans in germ cells. These dynamics coincide with 
the timing and cell specificity of GnT1IP expression in testes, 
especially GnT1IP-L (Fig. 9). Other evidence of the importance 
of N-glycans in germ-Sertoli cell interactions comes from the 
ManIIx knockout mouse that permanently lacks a subset of 
complex N-glycans, leading to increased expression of high 
mannose and hybrid N-glycans (Akama et al., 2002, 2006). 
Males lacking ManIIx exhibit defective adhesion of germ cells 
to Sertoli cells, release immature germ cells into epididymis, 
and are sterile (Akama et al., 2002).
Complex N-glycans are essential for mammalian de-
velopment beyond mid-gestation (Ioffe and Stanley, 1994; 
with or mislocalize the trans-Golgi or TGN glycosyltransferases 
4GalT-1 and STX, and does not inhibit 4GalT or GlcNAcT-III 
enzyme activity.
The inhibitory function of GnT1IP contrasts with previous 
examples of glycosyltransferase complexes, which are required 
to induce, promote, or preserve enzyme activity (Giraudo et al., 
2001; Akasaka-Manya et al., 2006; Seko and Yamashita, 2008; 
Aryal et al., 2010). Membrane-bound GnT1IP causes dominant 
inhibition of GlcNAcT-I that could be useful for glycosylation 
engineering. Thus, transient expression of GnT1IP in cells   
expressing recombinant therapeutic antibodies could be used for 
rapid testing of the effect of converting complex to high mannose 
N-glycans on antibody-dependent cellular cytotoxicity (ADCC; 
Carter, 2001; Kanda et al., 2007; Mori et al., 2007). High man-
nose N-glycans have little core fucosylation and induce ADCC 
much more effectively than IgG with a complex fucosylated   
N-glycan (Zhou et al., 2008). Although most glycoproteins with 
high mannose N-glycans are removed from serum by the liver 
within minutes, antibodies with high mannose N-glycans have a 
longer lifespan (Millward et al., 2008; Zhou et al., 2008).
Importantly, mouse GnT1IP is expressed almost solely in 
testes (Chalmel et al., 2007), and the splice form producing 
transmembrane GnT1IP-L is confined to testicular germ cells, 
beginning with spermatocytes and being down-regulated after 
the spermatid stage (Fig. 8). GnT1IP-S is found in spermatids 
and probably spermatocytes, but is predicted not to inhibit 
Figure 9.  Summary diagram. The relative levels of GnT1IP-L and GlcNAcT-I transcripts in germ cells vary during spermatogenesis as indicated (Chalmel 
et al., 2007; Fig. 8), and the N-glycans on germ cells vary as shown by changes in lectin binding (Jones et al., 1992). In spermatogonia, negligible levels 
of the new GlcNAcT-I inhibitor GnT1IP-L described herein, and high GlcNAcT-I leads to the synthesis of complex N-glycans. In spermatocytes, increased 
expression of GnT1IP-L accompanied by down-regulation of GlcNAcT-I leads to the expression of high mannose N-glycans on germ cell glycoproteins. This 
change in N-glycans is predicted to enhance the binding of spermatocytes to Sertoli cells (Fig. 8). At later stages of spermatogenesis GnT1IP-L expression 
levels decrease while GlcNAcT-I levels increase, and spermatids express complex N-glycans and have reduced binding to Sertoli cells.JCB • VOLUME 190 • NUMBER 5 • 2010   906
or pcDNA3/Neo expression vectors using primers 5-GAGACTGAGCTC-
CACCATGAAGGCCAAGAACGTTAACTTGCTCTTC-3 and 5-CTCTGAG-
GATCCCTAGTAATAATTATCCTTGAGGTGCTG-3. GnT1IP-S was fused with 
Myc (
2EQKLISEEDL
11) for Myc-GnT1IP-S or fused with FL-HA (
2DYKDDDD-
KGSYPYDVPDYASLRPLE
26)  for  FL-HA-GnT1IP-S.  For  Myc-stem-GnT1IP-S, 
aa 27–74 of GnT1IP-S were deleted. For Myc- or FL-HA-GnT1IP-S-CD1, the   
C-terminal 334–373 aa of GnT1IP-S were deleted. For Myc- or FL-HA- 
GnT1IP-S-CD2, the C-terminal 252–373 aa of GnT1IP-S were deleted. For the 
E253A or D255A mutations of GnT1IP-S, Myc-GnT1IP-S was used as tem-
plate in combination with the QuikChange XL site-directed mutagenesis kit 
(Agilent Technologies) and primers 5-CCAAGGCCACGTATTATTTACAGC-
TAGCAGATGATATCGTAGCAA-3’  and  5-TTGCTACGATATCATCTGCTA-
GCTGTAAATAATACGTGGCCTTGG-3’ for Myc-GnT1IP-S (ADD), or with   
primers  5-CCAAGGCCACGTATTATTTACAGCTAGAAGATGCTATCGTA-
GCAA-3’  and  5’-TTGCTACGATAGCATCTTCTAGCTGTAAATAATACGTG-
GCCTTGG-3’ for Myc-GnT1IP-S (EDA). For GnT1IP-S-KDEL, the 
374KDEL
377 
sequence was fused after aa 373 of GnT1IP-S by PCR. An HA (
27YPYDVP-
DYASL
37) or Myc (
27EQKLISEEDL
36) tag was inserted between aa 26 and 27 
of GnT1IP-S by PCR for SP-iTag2-GnT1IP-S. For GnT1IP-S-HA, HA (
374YPY-
DVPDYASL
384) was fused after aa 373 of GnT1IP-S. For C-terminal HA or 
Myc-tagged CHO GlcNAcT-I, HA (
448YPYDVPDYASL
458) or Myc (
448EQKLI-
SEEDL
457) was fused after aa 447 of GlcNAcT-I (Chen and Stanley, 2003) 
and cloned into pcDNA3.1/Hygro between HindIII and XbaI for GlcNAcT-
I-HA or HindIII and BamHI for GlcNAcT-I-Myc. For GlcNAcT-I-HA-KDEL, the 
HA tag and 
458SEKDEL
464 sequences were fused after aa 447 of CHO 
GlcNAcT-I and cloned into pcDNA3.1/Hygro between HindIII and BamHI. 
For C-terminal HA-tagged mouse GlcNAcT-III, HA (
539YPYDVPDYA
547) was   
fused after aa 538 of GlcNAcT-III (Bhattacharyya et al., 2002) and cloned   
into pcDNA3.1/Hygro between HindIII and BamHI. For C-terminal HA-tagged 
mouse ManIIx, ManIIx DNA sequence was amplified from mouse testis cDNA 
and  the  HA  (
1153YPYDVPDYA
1161)  sequence  was  fused  after  aa  1152  of   
ManIIx (Akama et al., 2006) and cloned into pcDNA3.1/Hygro between 
HindIII  and  BamHI.  For  C-terminal  HA-tagged  bovine  SGT,  which  lacks   
N-terminal 13 aa of bovine 4GalT-I, HA (
390YPYDVPDYA
398) was fused after 
aa 389 of bovine SGT. Bovine SGT was amplified from a pSVL vector contain-
ing a bovine 4GalT-I cDNA, a gift of Joel Shaper (Johns Hopkins Medicine, 
Baltimore, MD; Russo et al., 1990), and cloned into pcDNA3.1/Hygro be-
tween BamHI and XbaI. STX-HA was amplified from pcDNA3 containing a 
mouse St8sia2 cDNA, a gift from Rita Gerardy-Schahn (Medizinische Hoch-
schule, Hannover, Germany), and cloned in pcDNA3.1/Hygro between KpnI 
and XbaI. N-terminal HA-tagged human p85ni, consisting of the iSH2 and 
nSH2 domains of PI3K (aa 320–600) (Wu et al., 2009), was a gift of Jona-
than Backer (Albert Einstein College of Medicine, New York, NY).
Cell culture
HeLa cells were from the late Dennis Shields (Albert Einstein College of Medi-
cine, New York, NY). CHO cells were grown and maintained in -modified 
Eagle’s medium with 10% FBS (Gemini Bio-Products) in suspension or on 
plates incubated in 5% CO2 at 37°C. HeLa cells were grown and main-
tained in DME with 10% FBS on plates in 5% CO2 at 37°C. Sertoli TM4 cells 
(CRL-1715)  and  15P-1  (CRL-2618)  Sertoli  cells  were  obtained  from  the 
American Type Culture Collection (Manassas, VA) and maintained in me-
dium containing a 1:1 mixture of DME and Ham’s F12 medium, 5% horse 
serum, 2.5% FBS, 2.5 mM  l-glutamine, 15 mM Hepes, 0.5 mM sodium   
pyruvate, and 1.2 g/L sodium bicarbonate.
Transfection methods
Expression constructs were transfected using Fugene 6 (Roche) or polyethyl-
enimine (PEI). For Fugene 6, cells cultured on plates overnight were trans-
fected according to the manufacturer’s instructions with 3 µl Fugene per g 
vector. For PEI, 11 mg PEI (PEI87K, a gift of Robert Haltiwanger, Stony Brook 
University, NY) was dissolved in 10 ml distilled water, sterilized by filtration, 
and frozen at 80°C. After 2 h, the PEI solution was thawed at 37°C and 
the cycle was repeated two more times before transfection. PEI and DNA 
were added to separate tubes containing medium in a ratio of 3 µl:1 µg, 
then mixed and incubated for 10 min at room temperature. The mixture was 
added drop-wise to cells on a plate containing culture medium and incu-
bated at 37°C overnight. For immunoprecipitation experiments, 3.4 × 10
7 
CHO cells were plated on a 10-cm plate overnight before PEI transfection. 
For immunofluorescence microscopy, HeLa cells were plated on poly-l- 
lysine–coated coverslips on a 6-well plate at 1.5 × 10
5 cells/well and incu-
bated for 16 h at 37°C in 5% CO2 before Fugene 6 or PEI transfection. Cells 
were collected from plates by scraper, trypsin, or enzyme-free Cell Dissocia-
tion Solution (Millipore) or fixed for immunofluorescence microscopy.
To obtain stable transfectant cell populations, antibiotic selection 
was started 24–48 h after transfection by adding 10
6 transfectants to 
Metzler et al., 1994). They carry sugar determinants recog-
nized by selectins and galectins that mediate cell adhesion 
and migration (Cummings and Esko, 2009; Cummings and 
Liu, 2009) and regulate growth factor signaling (Zhao et al., 
2008; Dennis et al., 2009; Song et al., 2010). Interestingly, 
mouse GlcNAcT-I is highly expressed in spermatogonia and 
down-regulated in spermatocytes and spermatids, in a com-
plementary expression pattern with GnT1IP (Chalmel et al., 
2007).  Thus,  reduced  expression  of  GlcNAcT-I  coincides 
with up-regulation of GnT1IP, both leading to increased ex-
pression of high mannose N-glycans and enhanced Sertoli–
germ cell binding during differentiation from spermatocytes 
to spermatids (Fig. 9). The question of whether temporary in-
hibition of GlcNAcT-I during spermatogenesis is required for 
male fertility awaits the generation of GnT1IP conditional 
knockout mice, but is of interest for human spermatogenesis. 
GnT1IP expression is also highly restricted to human testes 
(Hodgson et al., 2006; Chalmel et al., 2007) and transcript 
levels of human GnT1IP (Ensembl, gene ID: AC093671.1) 
are misregulated in some forms of human spermatogenic fail-
ure including patients with Sertoli Cell Only syndrome, or 
men with many early spermatids but no late spermatids, in 
which a fourfold decrease in GnT1IP transcripts was observed 
(Spiess et al., 2007).
Materials and methods
RNA isolation and RT-PCR
Testes from adult mice were homogenized in TRIzol (Invitrogen), extracted 
with chloroform and isopropyl alcohol, and the RNA precipitate was dissolved 
in RNase-free water and stored at 80°C. Total RNA (1–2 µg) was used 
to synthesize cDNA primed by oligo-dT (T12-18; Invitrogen) and extended 
using  SuperScript  II  reverse  transcription  (Invitrogen).  Control  reactions 
contained double-distilled water in place of reverse transcription. After   
50 min elongation at 42°C, reactions were stopped at 70°C for 10 min and 
stored at 20°C. Partially purified mouse spermatocytes or spermatids 
provided by Paula Cohen (Cornell University, NY) were lysed and con-
verted into cDNA using the Cells-to-cDNA II kit (Applied Biosystems). Primer 
pairs used for detecting GnT1IP-S and -L transcripts were: pair 1, 5-GATTG-
TAAAGTGTGGTCAAGAGGGGC-3:  5-GGGTAAAGTTTCCCTGCTGTC-
CTTA-3; pair 2, 5-TGTGCAGCCTGGTGTTGGCAGT-3: 5-GGGTAAAG-
TTTCCCTGCTGTCCTTA-3; pair 3, 5-TGTGCAGCCTGGTGTTGGCAGT-3:   
5-GAGAAAATTTGATATTTGCTGTGCC-3; pair 4, 5-ATGTGCCTGGGA-
GAAAGTGTTGGGGACC-3:  5-GAGAAAATTTGATATTTGCTGTGCC-3; 
pair 5, 5-TGTGCAGCCTGGTGTTGGCAGT-3: 5-TCGGTCATGCATTC-
CACATGAGTTTACAGGA-3; pair 6, 5-ATGTGCCTGGGAGAAAGTGTT-
GGGGACC-3: 5-GGGTAAAGTTTCCCTGCTGTCCTTA-3; pair 7, 5-ATG-
AAGGCCAAGGACGTTAACTTGC-3: 5-GGGTAAAGTTTCCCTGCTGTC-
CTTA-3; pair 8, 5-ATGAAGGCCAAGGACGTTAACTTGC-3: 5-GAGA-
AAATTTGATATTTGCTGTGCC-3. GlcNAcT-I transcripts were detected with 
primers 5- CCAAGCTTCTCCCKGYGGGGGCCAGG-3: 5-GGCRGAG-
CCCAGRARGGAMAGGCAGGWGCT-3 (Chen and Stanley, 2003) and 
-actin with primers 5-GTGGGCCGCTCTAGGCACCA-3: 5-TGGCCT-
TAGGGTTCAGGGGG-3.
cDNA constructs
GnT1IP-L and related cDNAs were cloned into pcDNA3.1/Hygro (hy-
gromycin) or pIRES2-EGFP/Neo (neomycin or G418) or pcDNA3/Neo 
vectors using primers 5-GAGACTGAGCTCCACCATGTGCCTGGGAGA-
AAGTGTTGGGGACC-3 and 5-TCGAGTCGACCTAGTAATAATTATCCTT-
GAGGTGCTG-3’. HA-GnT1IP-L and Myc-GnT1IP-L were constructed with 
HA (
2YPYDVPDYASL
12) and Myc (
2EQKLISEEDL
11) fused at the N terminus   
of  GnT1IP-L,  respectively.  Myc  was  also  fused  at  the  C  terminus  of   
GnT1IP-L  after  417  aa  (
418EQKLISEEDL
427)  for  GnT1IP-L-Myc  or  after 
412 aa (
413EQKLISEEDL
422) for GnT1IP-L-Myc-KDNYY (GnT1IP-L-iTag1). For 
Myc-stem-GnT1IP-L, aa 71–118 of GnT1IP-L were deleted. GnT1IP-S and   
related constructs were cloned into pcDNA3.1/Hygro or pIRES2-EGFP/Neo 907 A novel inhibitor of GlcNAcT-I • Huang and Stanley
3H-GlcNAc  incorporated  into  Con  A–Sepharose-fractionated  product   
in the presence versus the absence of substrate was used to determine 
specific activity.
4GalT activity was assayed in 50 µl reaction as described previ-
ously (Lee et al., 2001). The reaction contained 5 µmol 2-(N-morpholino) 
ethanesulfonate buffer, pH 6.5, 3 µmol MnCl2, 1.2% Triton X-100, 35 nmol 
UDP-[6-
3H]-Gal (10,000–30,000 cpm/nmol; PerkinElmer), with or without 
10 mM GlcNAc acceptor, and 50–100 µg cell lysate. After 2 h incubation 
at 37°C, reactions were stopped by adding 1 ml cold water and then pass-
ing through a 1-ml column of AG1-X4 (Cl
 form; Bio-Rad Laboratories) that 
was subsequently washed with 2 ml distilled water to obtain 
3H-Gal–labeled 
products. Specific activity was determined from 
3H-Gal incorporated in the 
presence versus the absence of GlcNAc.
Western analysis
Cell lysates were prepared from saline-washed stable cell lines or transient 
transfectants 1–2 d after transfection in buffer containing 75 µl of 1.5% Tri-
ton X-100 (Sigma-Aldrich) and 1× protease inhibitor cocktail in water per 
10
7 cells. Lysate protein concentrations were determined by Dc protein   
assay (Bio-Rad Laboratories). For electrophoresis, lysates were loaded on 
10% Tris-HCl polyacrylamide gels at 10–30 mA for 2 h. Proteins were 
transferred to polyvinylidene difluoride (PerkinElmer) membrane overnight 
at 50 mA in a transfer buffer containing 10% methanol. For immunoblot-
ting, primary and secondary antibodies were diluted in Tris-buffered saline 
(10 mM Tris HCl, pH 7.4, and 150 mM NaCl) containing 0.05% Tween 
20 (Sigma-Aldrich) and 3% nonfat dry milk (wt/vol) supplemented with 3% 
(wt/vol) BSA or 3% nonfat dry milk, respectively. Anti-Myc mAb (9E10) 
was  diluted  1:500,  anti-HA  mAb  (HA.11)  1:1,000,  anti-  actin  mAb 
1:5,000,  and  HRP-conjugated  goat  anti–mouse  secondary  antibody 
1:5,000–10,000. The membrane was washed with the same Tris-buffered 
saline containing 0.05% Tween 20, incubated with Super Signal West Pico 
chemiluminescence reagent (Thermo Fisher Scientific), and exposed to film 
(Denville Scientific, Inc.).
Endoglycosidase digestions
Endoglycosidase H (Endo H) from Streptomyces plicatus was from Roche 
and Peptide N-glycosidase F (PNGase F) from Flavobacterium meningo-
septicum was from New England Biolabs, Inc. PNGase F and Endo H 
treatments of lysates were performed as suggested by the manufacturers at 
37°C for 18 h in 20-µl buffers provided by the manufacturers. Lysates of 
100–200 µg of protein were treated with 1,000 units of PNGase F or 
Endo H. Enzyme was replaced by water for control reactions. Reactions 
were stopped by the addition of gel loading buffer and heating at 95°C 
for 10 min followed by SDS-PAGE.
Immunofluorescence and confocal microscopy
Cells were plated at 3 × 10
5 cells/well on poly-l-lysine–coated coverslips 
on a 6-well plate and incubated for 16 h at 37°C in 5% CO2. After wash-
ing with PBS, cells were fixed in 3% (wt/vol) paraformaldehyde, then incu-
bated with blocking buffer supplemented with 0.2% Triton X-100, 1% FBS, 
and 0.5% (wt/vol) BSA in PBS with Ca
2+ and Mg
2+ as described previously 
(Chiu et al., 2002; Mukherjee et al., 2007). After first and secondary anti-
body incubations, blue DAPI (1 µg/ml; Sigma-Aldrich) was used for nu-
clear staining. Antibodies and DAPI were diluted in the same blocking 
buffer containing 0.2% Triton X-100 as described above. Cells were mounted 
using Fluoromount (SouthernBiotech). For selective permeabilization of 
plasma  membrane,  slides  were  first  incubated  with  5  µg/ml  digitonin 
(EMD) in 10 mM Hepes buffer containing 0.3 M sucrose, 2.5 mM MgCl2, 
0.1 M KCl, and 1 mM EDTA at pH 6.9 for 15 min at 4°C, followed by first 
and secondary antibody incubations except that no detergent was added 
to the blocking buffer. Immunofluorescent images were digitally acquired 
on an inverted microscope (Axiovert 200M; Carl Zeiss, Inc.) coupled to a 
12-bit cooled charge-coupled device camera (AxioCam MRm Rev. 3; Carl 
Zeiss, Inc.) controlled by Axiovision software (AxioVs40, version 4.7.2.0; 
Carl Zeiss, Inc.), using a 100x/1.3 NA oil immersion objective (EC Plan-
NeoFluar; Carl Zeiss, Inc.), and saved as tiff files (1388 × 1040, 8 bit). All 
pictures were treated identically using Adobe Photoshop to remove back-
ground and adjust contrast. Images of confocal microscopy were acquired 
by capturing Z-series images with a 0.25-µm step size on a confocal micro-
scope (TCS SP2 AOBS; Leica) using a 63x/1.4 NA oil immersion objec-
tive (HCX PL APO BL CS; Leica). Laser lines at 405-, 488-, and 561-nm 
were provided by 20 mW diode, 100 mW Ar, and 10 mW diode, respec-
tively; sequential excitation by line and detection range settings was used 
to eliminate cross talk between fluorophores. The images (512 × 512 
pixel, 8 bit) were saved as tiff files. The entire Z-series was projected using 
the sum intensity method provided by ImageJ (NIH).
selection media containing 1 mg/ml active G418 (Gemini Bio-Products) 
for 5–7 d or 1.4 mg/ml Hygromycin (EMD) for 1 d before switching to   
0.7 mg/ml Hygromycin for 4–6 d. Resistant colonies were pooled and 
used or sorted by fluorescence-activated cell sorting (FACS) for expression 
of GFP, or binding of GNA-FITC or L-PHA-FITC before use.
Antibodies and lectins
Anti-HA mouse mAb (HA.11) and anti-Myc mouse mAb (9E10) were from   
Covance; anti-HA rabbit polyclonal antibody (pAb; Y-11) was from Santa 
Cruz Biotechnology, Inc.; anti-Xenopus laevis -actin mAb (AC-15) was from 
Abcam; anti–human Golgi matrix protein GM130 rabbit pAb and anti–rat 
Golgi matrix protein GM130 mouse mAb (35/GM130) were from EMD and 
BD, respectively; goat HRP-conjugated anti–mouse secondary antibody was 
from Thermo Fisher Scientific; anti–bovine PDI rabbit pAb and anti–rat PDI 
mouse mAb (1D3) were from Stressgen; Phalloidin conjugated with Alexa 
568 (red) was from Invitrogen; anti–human ERGIC-53 mouse mAb (G1/93) 
was from Enzo Life Sciences, Inc.; anti–human 4GalT-I rabbit polyclonal anti-
bodies (pAb) were a gift from Eric Berger (University of Zurich, Zurich, Switzer-
land); anti–human ManII rabbit pAb was a gift from Kelly Moremen (University 
of Georgia, Athens, GA); and Alexa 488 (green) goat anti–rabbit or anti–
mouse secondary antibodies and Alexa 568 (red) goat anti–mouse IgG (H+L) 
secondary antibody were from Invitrogen. Plant lectins Con A, Phaseolus   
vulgaris leucoagglutinin (L-PHA), wheat germ agglutinin (WGA), Galanthus   
nivalis lectin GNA-FITC, and L-PHA-FITC were from Vector Laboratories.
Lectin resistance test
To determine lectin resistance, 2,000 CHO cells in medium containing 
10% FBS (100 µl) were added to each well of a 96-well plate. Lectins (100 µl) 
in medium containing 10% FBS were added at increasing concentrations. 
After 4 d at 37°C in the 5% CO2 incubator, or when control wells were 
confluent, the medium was removed and the cells were fixed and stained 
with Methylene Blue in 50% methanol.
Flow cytometry analysis and FACS
For flow cytometry, cells were washed once with 1 ml cold FACS binding 
buffer (1x HBSS containing 1 mM CaCl2, 1 mM MgCl2, 0.05% or 0.1% 
sodium azide, and 2% BSA Fraction V [Sigma-Aldrich]). Cells were incu-
bated with 12 µg/ml GNA-FITC lectin in FACS buffer for 30 min on ice, 
washed with 1 ml FACS binding buffer, and the cell pellet was resuspended 
in 0.5 ml FACS buffer, without BSA, and subjected to FACSscan (BD) flow 
cytometer for FACS analysis. Raw data were processed by Flowjo software 
(Tree Star, Inc.) after 7-Amino-actinomycin D (BD)–positive cells were gated 
out. For cell sorting, cells were washed with FACS binding buffer without 
sodium  azide  and  incubated  in  the  same  buffer  containing  12  µg/ml 
GNA-FITC or L-PHA-FITC. After 1 h on ice-water the cells were washed 
once with 1 ml cold FACS buffer, resuspended in 0.5 ml FACS buffer con-
taining penicillin (100 units) and streptomycin (100 µg/ml; Invitrogen) and 
amphotericin B (2.50 µg/ml; Invitrogen), and subjected to flow cytometry 
(Dako MoFlo and Dako MoFlo XDP) to sort GNA- or L-PHA-binding cells 
after  gating  out  7-Amino-actinomycin  D–positive  cells.  Cells  expressing 
GFP were sorted similarly for high GFP expression.
GlcNAcT-I, GlcNAcT-III, and 4GalT enzyme assays
For enzyme assays, exponentially growing cells were washed three times 
in saline and lysed in 1.5% Triton X-100 in distilled water in the presence 
of  protease  inhibitor  cocktail  (Roche).  To  determine  GlcNAcT-I  activity, 
50 µg cell extract was incubated at 37°C for 2 h in the presence of 27 µg 
Man5GlcNAc2Asn (Huang and Montgomery, 1970; Chaney and Stanley, 
1986), 62.5 mM 2-(N-morpholino)ethanesulfonate (MES), pH 6.25, 25 mM 
MnCl2,  and  0.75  mM  UDP-[
3H]-GlcNAc  (10,000–20,000  cpm/nmol; 
PerkinElmer) in a final volume of 50 µl. Reactions were stopped by adding 
0.5 ml of Con A buffer (0.1 M sodium acetate, 1.0 M NaCl, 10 mM MgCl2, 
10 mM CaCl2, 10 mM MnCl2, and 0.02% sodium azide). After centrifuga-
tion in a microfuge for 5 min, the supernatant was added to a 1-ml column of 
Con A–Sepharose (GE Healthcare). After washing with Con A buffer, product 
was eluted with 200 mM -methylmannoside in Con A buffer. Specific activi-
ties were determined from 
3H-GlcNAc incorporated into Con A–bound prod-
uct in the presence versus the absence of acceptor Man5GlcNAc2Asn.
GlcNAcT-III activity was assayed in a 40-µl reaction as described 
previously (Bhaumik et al., 1998) containing 8 mol GlcNAc, 12.5 mM 
MnCl2, 6–8 mM UDP-[
3H]-GlcNAc (15,000–30,000 cpm/nmol), 1% Triton 
X-100, and 62.5 mM 1,4-piperazinediethanesulfonic acid sodium salt 
(Na Pipes; pH 7.0) with or without 40 µg substrate GlcNAc2Man3GlcNAc2 
(Seko et al., 1997) and 50–100 µg cell lysate. After 2 h incubation at 
37°C, the reaction was stopped by adding 0.5 ml of Con A buffer and JCB • VOLUME 190 • NUMBER 5 • 2010   908
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Brefeldin A treatment
Transfected cells were washed once with PBS containing 1 mM Ca
2+ and 
1 mM Mg
2+ and incubated with DME supplemented with 10% FBS and 
100 µg/ml CHX (DMSO stock solution; EMD) for 45 min or 1 h at 37°C in 
5% CO2. Cells were then incubated with new medium containing 10 µg/ml 
BFA (DMSO stock solution; Sigma-Aldrich) with or without 100 µg/ml   
CHX for another 30 min at 37°C in 5% CO2. Cells were then washed three 
times with cold PBS containing Ca
2+ and Mg
2+ and processed for immuno-
fluorescence microscopy.
Immunoprecipitation
Anti-Myc mAb (9E10) in 190 mM Hepes (pH 8.9) was incubated with 
Gammabind G sepharose (GE Healthcare; 5 mg IgG for 1 ml packed 
beads) for 6 h to overnight at 4°C. Beads were washed with 190 mM 
Hepes (pH 8.9) and bound antibodies were cross-linked by dimethyl 
dimelimidate dihydrochloride (11 mg/ml; Sigma-Aldrich) in 190 mM 
Hepes (pH 9.5) for 1 h at room temperature. The cross-linking reaction 
was  terminated  with  0.2  M  ethanolamine  (pH  8),  and  beads  were 
washed  extensively  with  PBS  and  stored  in  PBS  containing  0.01%   
thimerasol at 4°C. For coimmunoprecipitation, transfected cells were 
lysed with 800 µl lysis buffer (RIPA buffer [Millipore] containing 150 
mM NaCl, 1% NP-40, 0.5% deoxycolate, and 0.1% sodium dodecyl 
sulfate [SDS] in 50 mM Tris, pH 7.5) containing EDTA-free protease   
inhibitor cocktail (Roche). Lysates were centrifuged at 10,000 g for 20 min 
at 4°C. Supernatants were precleaned with 25 µl packed Gammabind 
G Sepharose for 4–6 h at 4°C, followed by immunoprecipitation with 
25 µl anti-Myc beads overnight at 4°C. Anti-Myc beads were washed 
three times with 1 ml fresh lysis buffer and once with 1 ml PBS, and ana-
lyzed  by  immunoblotting.  Two  separate  aliquots  of  anti-Myc  beads 
(each 40%) and two aliquots of 1/40th cell lysate were boiled at 95°C 
for 5 min in gel loading buffer containing 5% 2-mercaptoethanol and 
3% SDS. After electrophoresis on two separate 10% Tris-HCl polyacryl-
amide  gels,  proteins  were  transferred  to  polyvinylpyrolodine  (PVDF) 
membranes that were incubated with the indicated primary antibodies 
followed by HRP-coupled secondary antibodies. Signals were detected 
using the Super Signal West Pico chemiluminescence reagent (Thermo 
Fisher Scientific).
Sertoli cell adhesion assay
TM4 Sertoli cells were plated on a 12-well plate and used at 80–90% con-
fluence. CHO cells were labeled by incubation in warm PBS containing   
5 µM carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) reagent 
(Invitrogen) followed by 15 min incubation at 37°C. Then reagents were 
removed and cell pellets were resuspended in warm culture medium and 
incubated at 37°C for 30 min. The culture medium was removed, the cell 
pellet resuspended with 1x HBSS containing 1 mM Ca
2+, Mg
2+, and 2% 
BSA (wt/vol), and 3.5 × 10
5 cells were added to wells containing fixed 
TM4 Sertoli cells (3% [wt/vol] paraformaldehyde) and incubated at 37°C 
for 4 h. After incubation, wells were washed four times with 1.5 ml HBSS 
containing 1 mM Ca
2+, 1 mM Mg
2+, and 2% BSA and pictures were taken 
with a digital camera (10x/0.25 NA; A-Plan Ph1; Carl Zeiss, Inc.) via an 
inverted microscope (Axiovert 200M; Carl Zeiss, Inc.). Pictures were pro-
cessed by Adobe Photoshop and quantified by NIH ImageJ.
Online supplemental material
Fig. S1 shows cDNA and deduced protein sequence of GnT1IP-L and -S 
(GenBank/EMBL/DDBJ accession no. HM067443). Fig. S2 shows that 
nonmembrane-bound GnT1IP-S was modified with complex N-glycans and 
secreted, and partially colocalized with GlcNAcT-I. Fig. S3 shows MALDI-
TOF mass spectra of N-glycans from CHO cells expressing GnT1Ip-L or 
Myc-GnT1Ip-S. Fig. S4 shows membrane-bound GnT1IP-S was localized to 
the ER and early Golgi compartment like GnT1IP-L. Fig. S5 shows that dele-
tion constructs of GnT1IP interacted with medial-Golgi but not trans-Golgi 
enzymes. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201004102/DC1.
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